{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T10:34:01Z","timestamp":1774348441943,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"DOI":"10.1007\/s13730-025-01066-2","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T04:31:45Z","timestamp":1770265905000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A case of membranoproliferative glomerulonephritis-type IgA nephropathy modified by nintedanib"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1915-1340","authenticated-orcid":false,"given":"Yasushi","family":"Kunisho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Sofue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirona","family":"Nagano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Higashitani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Shiga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiko","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhei","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emi","family":"Ibuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuo","family":"Minamino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"1066_CR1","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/jjco\/hyv035","volume":"45","author":"Y Kitai","year":"2015","unstructured":"Kitai Y, et al. Onco-nephrology: current concepts and future perspectives. Jpn J Clin Oncol. 2015;45:617\u201328.","journal-title":"Jpn J Clin Oncol"},{"key":"1066_CR2","doi-asserted-by":"publisher","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-07-6307","volume":"68","author":"F Hilberg","year":"2008","unstructured":"Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, et al. Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008;68:4774\u201382.","journal-title":"Cancer Res"},{"key":"1066_CR3","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071\u201382.","journal-title":"N Engl J Med"},{"key":"1066_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-017-1384-2","volume":"11","author":"I Ismail","year":"2017","unstructured":"Ismail I, Nigam S, Parnham A, Srinivasa V. Anti-glomerular basement membrane glomerulonephritis following nintedanib for idiopathic pulmonary fibrosis: a case report. J Med Case Rep. 2017;11:214.","journal-title":"J Med Case Rep"},{"issue":"2","key":"1066_CR5","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1681\/ASN.2018080853","volume":"30","author":"CC Estrada","year":"2019","unstructured":"Estrada CC, Maldonado A, Mallipattu SK. Therapeutic inhibition of VEGF signaling and associated nephrotoxicities. JASN. 2019;30(2):187\u2013200.","journal-title":"JASN"},{"key":"1066_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1159\/000088481","volume":"69","author":"MS Gordon","year":"2005","unstructured":"Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology. 2005;69:25\u201333.","journal-title":"Oncology"},{"key":"1066_CR7","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa021491","volume":"349","author":"JC Yang","year":"2003","unstructured":"Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427\u201334.","journal-title":"N Engl J Med"},{"key":"1066_CR8","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.ejca.2009.11.001","volume":"46","author":"H Izzedine","year":"2010","unstructured":"Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC. VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer. 2010;46:439\u201348.","journal-title":"Eur J Cancer"},{"issue":"11","key":"1066_CR9","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","volume":"358","author":"V Eremina","year":"2008","unstructured":"Eremina V, Jefferson JA, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358(11):1129\u201336.","journal-title":"N Engl J Med"},{"key":"1066_CR10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/ki.2013.344","volume":"85","author":"H Izzedine","year":"2014","unstructured":"Izzedine H, Mangier M, Ory V, Zhang SY, Sendeyo K, Bouachi K, et al. Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy. Kidney Int. 2014;85:457\u201370.","journal-title":"Kidney Int"},{"issue":"122","key":"1066_CR11","doi-asserted-by":"publisher","first-page":"ra39","DOI":"10.1126\/scisignal.2000678","volume":"3","author":"SY Zhang","year":"2010","unstructured":"Zhang SY, Kamal M, et al. c-mip impairs podocyte proximal signaling and induces heavy proteinuria. Sci Signal. 2010;3(122):ra39\u2013ra39.","journal-title":"Sci Signal."},{"key":"1066_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12072726","volume":"12","author":"M Tota","year":"2023","unstructured":"Tota M, Baron V, Musial K, et al. Secondary IgA nephropathy and IgA-associated nephropathy: a systematic review of case reports. J Clin Med. 2023;12:2726.","journal-title":"J Clin Med"},{"issue":"21","key":"1066_CR13","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000020464","volume":"99","author":"K Tanabe","year":"2020","unstructured":"Tanabe K, et al. Nivolumab-induced IgA nephropathy in a patient with advanced gastric cancer: a case report. Medicine (Baltimore). 2020;99(21):e20464.","journal-title":"Medicine (Baltimore)"},{"key":"1066_CR14","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s13730-020-00474-w","volume":"9","author":"M Hasegawa","year":"2020","unstructured":"Hasegawa M, Uehara A, Suzuki T, Sekine R, Yazawa M, Ichikawa D, et al. Nintedanib-induced glomerular microangiopathy: a case report. CEN Case Rep. 2020;9:295\u2013300.","journal-title":"CEN Case Rep"},{"key":"1066_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.5414\/CN109900","volume":"93","author":"D Inoue","year":"2020","unstructured":"Inoue D, Nishi H, Honda K, Ishii T, Abe H, Sato M, et al. Renal thrombotic microangiopathy during nintedanib treatment for idiopathic pulmonary fibrosis. Clin Nephrol. 2020;93:47\u201350.","journal-title":"Clin Nephrol"},{"key":"1066_CR16","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1159\/000517692","volume":"11","author":"T Fujita","year":"2021","unstructured":"Fujita T, Nakagawa H, Yokota T, Umetani J, Nagawa D, Nakata M, et al. Nintedanib-induced renal thrombotic microangiopathy. Case Rep Nephrol Dial. 2021;11:227\u201332.","journal-title":"Case Rep Nephrol Dial"},{"key":"1066_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0281945","volume":"18","author":"T Sofue","year":"2023","unstructured":"Sofue T, Oguchi H, Yazawa M, et al. Serological and histopathological assessment of galactose-deficient immunoglobulin A1 deposition in kidney allografts: a multicenter prospective observational study. PLoS ONE. 2023;18:e0281945.","journal-title":"PLoS ONE"},{"key":"1066_CR18","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2215\/CJN.11470918","volume":"14","author":"G Bayer","year":"2019","unstructured":"Bayer G, Von Tokarski F, Thoreau B, Bauvois A, Barbet C, Cloarec S, et al. Etiology and outcomes of thrombotic microangiopathies. Clin J Am Soc Nephrol. 2019;14:557\u201366.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1066_CR19","doi-asserted-by":"publisher","first-page":"1088031","DOI":"10.3389\/fphar.2022.1088031","volume":"13","author":"T Mazzierli","year":"2023","unstructured":"Mazzierli T, Allegretta F, Maffini E, Allinovi M. Drug-induced thrombotic microangiopathy: an updated review of causative drugs, pathophysiology, and management. Front Pharmacol. 2023;13:1088031.","journal-title":"Front Pharmacol"},{"issue":"2","key":"1066_CR20","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/ndt\/gft465","volume":"29","author":"V C\u00e9cile","year":"2014","unstructured":"C\u00e9cile V, Nolwenn L, et al. All anti-vascular endothelial growth factor drugs can induce \u2018pre-eclampsia-like syndrome\u2019: a RARe study. Nephrol Dial Transplant. 2014;29(2):325\u201332.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"1066_CR21","first-page":"39","volume":"27","author":"MJ Mihatsch","year":"1995","unstructured":"Mihatsch MJ, Morozumi K, Str\u00f8m EH, Ryffel B, Gudat F, Thiel G. Renal transplant morphology after long-term therapy with cyclosporine. Transplant Proc. 1995;27(1):39\u201342.","journal-title":"Transplant Proc"},{"key":"1066_CR22","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.humpath.2015.10.013","volume":"49","author":"T Kusano","year":"2016","unstructured":"Kusano T, Takano H, Kang D, Nagahama K, Aoki M, Morita M, et al. Endothelial cell injury in acute and chronic glomerular lesions in patients with IgA nephropathy. Hum Pathol. 2016;49:135\u201344.","journal-title":"Hum Pathol"},{"issue":"3","key":"1066_CR23","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s13730-024-00961-4","volume":"14","author":"S Hatanaka","year":"2025","unstructured":"Hatanaka S, Kanzaki G, Koike K, Ueda H, Matsuo N, Maruyama Y, et al. Effective combination of corticosteroid and cyclosporine A for immunoglobulin A nephropathy with membranoproliferative glomerulonephritis features: a case report. CEN Case Rep. 2025;14(3):486\u201392.","journal-title":"CEN Case Rep"},{"key":"1066_CR24","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.humpath.2018.06.031","volume":"81","author":"NK Andeen","year":"2018","unstructured":"Andeen NK, Jefferson JA, Akilesh S, Alpers CE, Bissonnette ML, Finn LS, et al. IgA-dominant glomerulonephritis with a membranoproliferative pattern of injury. Hum Pathol. 2018;81:272\u201380.","journal-title":"Hum Pathol"}],"updated-by":[{"DOI":"10.1007\/s13730-026-01106-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000}}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-025-01066-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-025-01066-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-025-01066-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T07:42:32Z","timestamp":1774338152000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-025-01066-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["1066"],"URL":"https:\/\/doi.org\/10.1007\/s13730-025-01066-2","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"17 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the original article, \u201cmembranous proliferative glomerulonephritis\u201d was incorrectly used instead of the standard term membranoproliferative glomerulonephritis.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s13730-026-01106-5","URL":"https:\/\/doi.org\/10.1007\/s13730-026-01106-5","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures involving human participants were performed in accordance with the ethical standards of the institutional and\/or national research committee and the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from an individual participant included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"44"}}